Low‐Molecular‐Weight Heparins: Are they all the Same?
- 1 April 2003
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 121 (1) , 12-20
- https://doi.org/10.1046/j.1365-2141.2003.04196.x
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Dalteparin vs. Enoxaparin as Prophylaxis for Deep-Vein Thrombosis After Total Hip or Knee ArthroplastyAmerican Journal of Physical Medicine & Rehabilitation, 2001
- Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgeryBritish Journal of Surgery, 2001
- Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysisThe Lancet, 2000
- Hotline sessions of the 21st European Congress of CardiologyPublished by Oxford University Press (OUP) ,1999
- Occurrence of thrombosis and haemorrhage, relationship with anti‐Xa, anti‐IIa activities, and D‐dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgeryBritish Journal of Haematology, 1999
- Low-Molecular-Weight HeparinsNew England Journal of Medicine, 1997
- A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery DiseaseNew England Journal of Medicine, 1997
- Dose-Ranging Trial of Enoxaparin for Unstable Angina: Results of TIMI 11AJournal of the American College of Cardiology, 1997
- Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemiaJournal of the American College of Cardiology, 1995
- A comparison of the antithrombotic effects of heparin and of low molecular weight heparins with increasing antifactor Xa/antifactor IIa ratio in the rabbitBritish Journal of Haematology, 1993